---

Diagnosis: Coccydynia (Coccygodynia) - Type III Coccyx with Internal Curvature

Clinical Correlation

---

Coccyx Morphological Classification (Maigne)

• Type I - Slightly curved, convexity directed posteriorly (normal variant)
• Type II - More marked curvature, moderate forward curve
• Type III - Sharp anterior angulation (the "internally curved" coccyx in this case), with angulation typically >90° on MRI/lateral X-ray. This type has significant clinical relevance as it is associated with coccydynia and impingement on the seat surface during sitting.
• Type IV - Subluxed or dislocated at the sacrococcygeal or intercoccygeal joint

• Obese patients: mainly posterior subluxation
• Normal-weight patients: hypermobility or normal
• Thin patients: mainly anterior subluxation and spicules (Type III-like)

---

Investigations Summary

• MRI: Confirms the Type III angulation, helps rule out chordoma, demonstrates sacrococcygeal inflammation
• Dynamic X-rays (sitting + standing): Gold standard for measuring coccygeal mobility, sagittal rotation, and the angle of incidence (angle at which coccyx strikes the seat)
• The "three angulations" noted on MRI likely refers to the sharp forward curvature of the coccyx segments characteristic of Type III

---

Management

Step 1 - Conservative (First-line, ~90% success overall)

1. NSAIDs - first-line analgesic/anti-inflammatory
2. Donut (coccyx-relief) cushion - offloads pressure from the coccyx during sitting
3. Activity modification - avoid prolonged sitting on hard surfaces
4. Physical therapy - pelvic floor relaxation, levator ani stretching
5. Stool softeners - to reduce pain during defecation

Step 2 - Interventional (When conservative fails)

• Patient prone, legs slightly abducted, feet "pigeon-toed"
• 22-gauge 3.5-inch spinal needle placed in midline, bevel facing ventrally
• Guided to the vestigial disc at point of maximal tenderness under C-arm AP + lateral views
• Aspiration to exclude blood, then 0.5 mL contrast to confirm placement
• Inject preservative-free lidocaine (without epinephrine) + betamethasone
• Key safety point: The rectum lies directly anterior - avoid overpenetration
• Excision is considered only if coccygeal injection with local anesthetic produces temporary but meaningful pain relief - if no relief with the anesthetic, surgery is unlikely to help

Step 3 - Surgical: Coccygectomy

• Failure of conservative + injection treatment (typically >3-6 months)
• Radiographic evidence of hypermobility or subluxation
• Type III or IV coccyx with confirmed impingement
• Painful diagnostic injection that gave temporary relief (confirms the coccyx is the pain generator)

---

Surgical Technique: Coccygectomy

1. Partial coccygectomy - resection of the mobile/angulated segment (appropriate for Type III where only the sharply angled segment is removed)
2. Total coccygectomy - complete removal of all coccygeal segments; may offer superior results in severe cases

1. Patient prone, general or spinal anesthesia
2. Midline incision over the sacrococcygeal junction
3. Careful subperiosteal dissection - preserve periosteal sleeve to reduce dead space
4. Identification and ligation of the middle sacral artery branches
5. Disarticulation at the sacrococcygeal joint (total) or at the relevant intercoccygeal joint (partial)
6. Critical: Keep dissection close to bone to protect the rectum anteriorly and the ganglion impar (sympathetic plexus) - injury causes risk of bowel/bladder dysfunction
7. Wound closure in layers - fascia, subcutaneous tissue, skin; some surgeons use drain

• Lower wound complication rate compared to midline
• Better blood supply at wound edges
• Recommended particularly when infection risk is high (obese patients, diabetics)

• Small incision with endoscopic visualization
• Reduced tissue trauma, shorter recovery
• Promising early outcomes but limited long-term data

---

Outcomes

---

Bottom Line for this Case

• Campbell's Operative Orthopaedics 15th Ed 2026, pp. 2421-2422
• Advances in Coccygectomy - Brain Sciences 2025 (PMID 40002545)
• Management of Coccygodynia - Ann Jt 2025 (PMID 39981432)

---

Revised Diagnosis and Management: 12-Year-Old Female with Type III Coccydynia

---

Why Age Matters Here - Key Anatomical Considerations

• Co1 ossified by age 6, lower segments (Co2-Co4) ossifying between 16 months and 18 years in a craniocaudal direction
• Fusion of coccygeal segments begins around age 6 but may continue until age 30 - this means the coccyx at 12 is still partially unfused and still maturing
• The Type III angulation (internally curved, sharp forward angulation) is a true structural morphological finding - not just developmental variation at this age
• Coccydynia accounts for <1% of all childhood low back pain cases - it is uncommon but genuine
• Females are affected 5:1 over males - this patient's demographics fit precisely
• The child cannot be managed with adult protocols - the developing coccyx requires a distinct, stepwise, more conservative-first approach

---

Diagnosis

• Pain + tenderness at coccygeal region: classic presentation
• Internally curved coccyx with >90° anterior angulation on MRI: confirms Type III
• MRI also rules out sinister pathology (chordoma, sacral tumor, infection) - important at this age

• Sacrococcygeal teratoma (rare but important)
• Pilonidal sinus
• Osteomyelitis of sacrum/coccyx
• Perianal abscess
• Spinal cord/tethered cord pathology (check for associated neurological signs)

---

Management in a 12-Year-Old (Stepwise)

Step 1 - Conservative (First-line, Minimum 3-6 Months)

Step 2 - Interventional (If Conservative Fails After 3-6 Months)

• Applicable in adolescents but requires pediatric anesthesia consideration
• Serves as both therapeutic and diagnostic - if no relief with local anesthetic, coccygectomy is unlikely to help
• Ganglion impar block is an alternative injection approach
• This step is more cautiously applied in children than adults

Step 3 - Surgical: Coccygectomy (Last Resort)

• Failure of conservative + injection treatment
• Confirmed structural Type III pathology on MRI (favorable prognostic sign for surgery)
• Significant impairment of daily life (school attendance, sitting, activities)
• Diagnostic injection provided temporary but meaningful relief

• 22 pediatric/adolescent patients aged 7-15 years (mean age ~10.9 years)
• 8 underwent coccygectomy (5 female, 3 male)
• Type III coccyx: ALL 3 cases required surgery - the highest surgical rate of any morphological type
• Results: 75% excellent, 25% good - no poor outcomes
• Mean hospital stay: 1.43 days
• No significant intraoperative or postoperative complications
• Parents satisfied in almost all cases on long-term follow-up

• Case series of patients aged 7-15: excellent or good outcomes in ALL cases after partial or total coccygectomy
• Retrospective cohorts show 68-76% success rate in pediatric/adolescent patients unresponsive to conservative treatment
• Coccygectomy is feasible, safe, and effective in children when appropriately indicated

---

Surgical Technique for this Patient

1. Position: Prone, legs slightly abducted
2. Incision: Midline over sacrococcygeal junction
3. Dissection: Subperiosteal - preserves periosteal sleeve, reduces dead space
4. Extent: Partial coccygectomy (resection of the angulated Type III segment) vs. total coccygectomy depending on intraoperative findings
   • In Type III, the sharply angled coccyx tip is the culprit - partial resection of the angulated segment is often sufficient
   • Total coccygectomy performed if multiple segments are abnormal
5. Critical safety: Rectum is directly anterior - dissection must stay on bone; fluoroscopic guidance helpful
6. Wound closure: Layered closure with minimal dead space; drain may be used

• Smaller incision, reduced tissue trauma, faster recovery
• Particularly attractive in a 12-year-old to minimize scarring and morbidity
• Limited long-term pediatric data but promising

---

Summary for this Patient

• Pediatric Coccydynia Narrative Review, Front Pediatr 2026 - PMID 41878453
• Coccygectomy in Pediatric/Adolescent Patients, J Indian Assoc Pediatr Surg 2021 - PMID 34083893
• Campbell's Operative Orthopaedics 15th Ed 2026, pp. 2421-2423

Can Cordarone (Amiodarone) Be Given with a Pulse of 80 bpm?

---

When Cordarone is CONTRAINDICATED regarding heart rate/rhythm:

---

Important Caution

• Monitor heart rate regularly after initiation
• If the HR drops significantly (especially below 50-55 bpm) or becomes symptomatic, reduce the dose
• Rarely, a pacemaker may be needed if severe drug-induced bradycardia develops

Summary

---

DRd Regimen - Daratumumab + Lenalidomide + Dexamethasone

---

1. DARATUMUMAB (Dara)

Dosing Schedule by Cycle

SC Route (Standard - preferred)

• Dose: 1800 mg fixed (flat dose) - no weight-based calculation needed
• Volume: 15 mL (comes pre-formulated at 120 mg/mL)
• Route: Subcutaneous injection into abdomen, ~7.5 cm to the right or left of navel
• Duration of injection: Over approximately 3-5 minutes
• No dilution required for SC formulation
• Observation: 1 hour after Cycle 1 Day 1 only; subsequent doses at clinician discretion

IV Route (if SC not available - weight-based dosing)

Filter: Always use a 0.2 micron in-line filter for IV daratumumab

---

2. LENALIDOMIDE (Len)

Lenalidomide Dose Reductions (Toxicity)

• CrCl 30-60 mL/min: 10 mg OD
• CrCl <30 mL/min (no dialysis): 7.5 mg OD
• Dialysis: 5 mg OD (give after dialysis)

---

3. DEXAMETHASONE (Dex)

After Cycle 1, steroid premedication before Dara may be reduced/omitted as infusion reaction risk significantly decreases after the 3rd dose.

---

PRE-MEDICATIONS (Before Every Daratumumab Dose)

---

SUPPORTIVE MEDICATIONS

---

INFUSION-RELATED REACTIONS (IRR) - Management

IRR incidence: ~3-4% with SC route (vs ~40% historically with IV), with median onset 3.5 hours post-injection. Observe SC patients for 6 hours after first dose.

---

QUICK REFERENCE SUMMARY

• SWAG Cancer Alliance DRd Protocol v1.2
• BC Cancer DRd Protocol (revised Dec 2024)
• Based on the MAIA trial (Facon et al., NEJM 2019)

---

Cellulitis Right Forearm - Presenting Complaints

Definition

---

PRESENTING COMPLAINTS (What the Patient Will Tell You)

1. Local Symptoms (Most Common Complaints)

2. Systemic Symptoms

3. Associated / Preceding History the Patient May Report

---

ON EXAMINATION (Findings Corresponding to Complaints)

---

SEVERITY CLASSIFICATION (Eron Classification - for Management Decisions)

---

HISTORY TAKING CHECKLIST (For Documentation)

• Duration of symptoms
• Onset - sudden or gradual
• Any preceding wound/bite/injection at the site
• Progression - is redness spreading?
• Associated fever, chills, sweating
• Any red streaks going up the arm
• Previous episodes of cellulitis

• Diabetes mellitus (most important risk factor)
• Immunosuppression (HIV, chemotherapy, steroids)
• Chronic venous/lymphatic disease
• Previous cellulitis at same site

---

CAUSATIVE ORGANISMS (for documentation)

• Most common: Streptococcus pyogenes (Group A Strep), Staphylococcus aureus
• MRSA: Suspect if purulent, failed initial antibiotics, or healthcare exposure
• Special situations: Vibrio vulnificus (seafood/seawater exposure), Pseudomonas (immunocompromised), Pasteurella multocida (animal bite)

---